Evidence map›Paper›PMID 25553797›Full record

ReviewCurrent topics in microbiology and immunology2015

IgE immunotherapy against cancer.

Lai Sum Leoh, Tracy R Daniels-Wells, Manuel L Penichet

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current topics in microbiology and immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. The causal effect of atopic dermatitis on lung cancer: A Mendelian randomization study.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024
    Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Isotype selection for antibody-based cancer therapy.Clinical and experimental immunology · 2021
    Review
  15. Review
  16. Article
  17. Antibody Isotypes for Tumor Immunotherapy.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2017
    Review
  18. Review
  19. mAbs
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Lai Sum LeohDivision of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, 10833 Le Conte Avenue, CHS 54-140, Box 951782, Los Angeles, CA, 90095-1782, USA.
Tracy R Daniels-Wells
Manuel L Penichet
University of California, Los Angeles · USComprehensive Cardiovascular · US

Funding

Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JAMIESON-KARAVODIN, BETH DEIRDRE · 1991 to 2018
$39.9M
Novel Nanopolymers to Inhibit Angiogenesis and Increase the Anti-tumor ImmunityR01CA136841 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LJUBIMOVA, JULIA Y, PENICHET, MANUEL L · 2010 to 2014
$2.7M
A Novel Anti-HER2/neu IgE for Breast Cancer TherapyR01CA181115 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PENICHET, MANUEL L · 2014 to 2018
$2.5M
Antibody-mediated Gene Therapy for the Treatment of CancerK01CA138559 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DANIELS-WELLS, TRACY RUTH · 2009 to 2013
$704k
A Novel IgE Cancer Therapeutic Specific for the Epithelial Membrane Protein-2R21CA179680 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DANIELS-WELLS, TRACY RUTH · 2013 to 2014
$362k
Development of an anti-PSA IgE to treat prostate cancerR41CA137881 · NCI · ADVANCED IMMUNE THERAPEUTICS, INC. · PI PENICHET, MANUEL L, SCHULTES, BIRGIT C · 2009 to 2009
$159k
NCI NIH HHS K01 CA138559NCI NIH HHS K01CA138559NCI NIH HHS R01 CA136841NCI NIH HHS R01CA136841NCI NIH HHS R01 CA181115NCI NIH HHS R01CA18115NCI NIH HHS R21 CA179680NCI NIH HHS R21CA179680NCI NIH HHS R41 CA137881NCI NIH HHS R41CA137881NIAID NIH HHS P30 AI028697
6 · The paper itself

Abstract

The success of antibody therapy in cancer is consistent with the ability of these molecules to activate immune responses against tumors. Experience in clinical applications, antibody design, and advancement in technology have enabled antibodies to be engineered with enhanced efficacy against cancer cells. This allows re-evaluation of current antibody approaches dominated by antibodies of the IgG class with a new light. Antibodies of the IgE class play a central role in allergic reactions and have many properties that may be advantageous for cancer therapy. IgE-based active and passive immunotherapeutic approaches have been shown to be effective in both in vitro and in vivo models of cancer, suggesting the potential use of these approaches in humans. Further studies on the anticancer efficacy and safety profile of these IgE-based approaches are warranted in preparation for translation toward clinical application.

Indexed as

AnimalsAntibodiesErb-b2 Receptor Tyrosine KinasesHumansImmunoglobulin EImmunotherapyMucin-1NeoplasmsProstate-Specific AntigenVaccinationAntibodiesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoglobulin EMucin-1Prostate-Specific Antigen

Identifiers

PMID25553797
PMCPMC4452505
OpenAlexW127827541

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.